User:Parth Vikram Singh

Jump to navigation Jump to search

Parth Vikram Singh, MBBS

Contact:Email: dr.parthvikramsingh@gmail.com

Medical Education

  1. Gibson CM, Singh PV. Contribution to:. Levacetylleucine In WikiDoc. https://www.wikidoc.org/index.php?title=Levacetylleucine
  2. Gibson CM, Singh PV. Contribution to: Crinecerfont. In WikiDoc. https://www.wikidoc.org/index.php?title=Crinecerfont
  3. Gibson CM, Singh PV. Contribution to: Revuforj. In WikiDoc. https://www.wikidoc.org/index.php?title=Revuforj
  4. Gibson CM, Singh PV. Contribution to: Inavolisib. In WikiDoc. https://www.wikidoc.org/index.php?title=Inavolisib
  5. Gibson CM, Singh PV. Contribution to: Umbralisib. In WikiDoc. https://www.wikidoc.org/index.php?title=Umbralisib
  6. Gibson CM, Singh PV. Contribution to: Melphalan flufenamide. In WikiDoc. https://www.wikidoc.org/index.php?title=Melphalan_flufenamide
  7. Gibson CM, Singh PV. Contribution to: Loncastuximab tesirine-lpyl. In WikiDoc. https://www.wikidoc.org/index.php?title=Loncastuximab_tesirine-lpyl
  8. Gibson CM, Singh PV. Contribution to: Sulopenem etzadroxil, probenecid. In WikiDoc. https://www.wikidoc.org/index.php?title=Sulopenem_etzadroxil,_probenecid
  9. Gibson CM, Singh PV. Contribution to: Deuruxolitinib. In WikiDoc. https://www.wikidoc.org/index.php?title=Deuruxolitinib
  10. Gibson CM, Singh PV. Contribution to: Miplyffa. In WikiDoc. https://www.wikidoc.org/index.php?title=Miplyffa
  11. Gibson CM, Singh PV. Contribution to: LetibotulinumtoxinA-wlbg. In WikiDoc. https://www.wikidoc.org/index.php?title=LetibotulinumtoxinA-wlbg
  12. Gibson CM, Singh PV. Contribution to: Tislelizumab. In WikiDoc. https://www.wikidoc.org/index.php?title=Tislelizumab-jsgr
  13. Gibson CM, Singh PV. Contribution to: Resmetirom. In WikiDoc. https://www.wikidoc.org/index.php?title=Resmetirom
  14. Gibson CM, Singh PV. Contribution to: Tarlatamab. In WikiDoc. https://www.wikidoc.org/index.php?title=Tarlatamab-dlle
  15. Gibson CM, Singh PV. Contribution to: Donanemab. In WikiDoc. https://www.wikidoc.org/index.php?title=Donanemab-azbt
  16. Gibson CM, Singh PV. Contribution to: Cabotegravir and rilpivirine. In WikiDoc. https://www.wikidoc.org/index.php?title=Cabotegravir_and_rilpivirine_(co-packaged)
  17. Gibson CM, Singh PV. Contribution to: Voclosporin. In WikiDoc. https://www.wikidoc.org/index.php?title=Voclosporin
  18. Gibson CM, Singh PV. Contribution to: Trilacicilib. In WikiDoc. https://www.wikidoc.org/index.php?title=Trilacicilib
  19. Gibson CM, Singh PV. Contribution to: Casimersen. In WikiDoc. https://www.wikidoc.org/index.php?title=Casimersen
  20. Gibson CM, Singh PV. Contribution to: Fosdenopterin. In WikiDoc.https://www.wikidoc.org/index.php?title=Fosdenopterin
  21. Gibson CM, Singh PV. Contribution to: Serdexmethylphenidate and dexmethylphenidate. In WikiDoc. https://www.wikidoc.org/index.php?title=Serdexmethylphenidate_and_dexmethylphenidate
  22. Gibson CM, Singh PV. Contribution to:   Drospirenone and estetrol. In WikiDoc. https://www.wikidoc.org/index.php?title=Drospirenone_and_estetrol
  23. Gibson CM, Singh PV. Contribution to: Pegcetacoplan. In WikiDoc. https://www.wikidoc.org/index.php?title=Pegcetacoplan
  24. Gibson CM, Singh PV. Contribution to: Amivantamab. In WikiDoc. https://www.wikidoc.org/index.php?title=Amivantamab-vmjw
  25. Gibson CM, Singh PV. Contribution to: Tivozanib. In WikiDoc. https://www.wikidoc.org/index.php?title=Tivozanib
  26. Gibson CM, Singh PV. Contribution to: Dostarlimab. In WikiDoc. https://www.wikidoc.org/index.php?title=Dostarlimab-gxly
  27. Gibson CM, Singh PV. Contribution to: Piflufolastat F 18. In WikiDoc. https://www.wikidoc.org/index.php?title=Piflufolastat_F_18
  28. Gibson CM, Singh PV. Contribution to: Sotorasib. In WikiDoc. https://www.wikidoc.org/index.php?title=Sotorasib
  29. Gibson CM, Singh PV. Contribution to: Infigratinib. In WikiDoc. https://www.wikidoc.org/index.php?title=Infigratinib
  30. Gibson CM, Singh PV. Contribution to: Olanzapine and samidorphan. In WikiDoc. https://www.wikidoc.org/index.php?title=Olanzapine_and_samidorphan
  31. Gibson CM, Singh PV. Contribution to: Vanzacaftor, tezacaftor, and deutivacaftor. In WikiDoc. https://www.wikidoc.org/index.php?title=Vanzacaftor,_tezacaftor,_and_deutivacaftor
  32. Gibson CM, Singh PV. Contribution to: Olipudase alfa. In WikiDoc. https://www.wikidoc.org/index.php?title=Olipudase_alfa
  33. Gibson CM, Singh PV. Contribution to: Eflapegrastim. In WikiDoc. https://www.wikidoc.org/index.php?title=Eflapegrastim
  34. Gibson CM, Singh PV. Contribution to: Gadopiclenol. In WikiDoc. https://www.wikidoc.org/index.php?title=Gadopiclenol
  35. Gibson CM, Singh PV. Contribution to: Oomidenepag isopropyl ophthalmic solution. In WikiDoc. https://www.wikidoc.org/index.php?title=Oomidenepag_isopropyl_ophthalmic_solution
  36. Gibson CM, Singh PV. Contribution to: Teclistamab. In WikiDoc. https://www.wikidoc.org/index.php?title=Teclistamab-cqyv
  37. Gibson CM, Singh PV. Contribution to: Mirvetuximab soravtansine. In WikiDoc. https://www.wikidoc.org/index.php?title=Mirvetuximab_soravtansine-gynx
  38. Gibson CM, Singh PV. Contribution to: Marstacimab. In WikiDoc. https://www.wikidoc.org/index.php?title=Marstacimab-hncq
  39. Gibson CM, Singh PV. Contribution to: Landiolol. In WikiDoc. https://www.wikidoc.org/index.php?title=Landiolol
  40. Gibson CM, Singh PV. Contribution to: Zolbetuximab. In WikiDoc. https://www.wikidoc.org/index.php?title=Zolbetuximab-clzb
  41. Gibson CM, Singh PV. Contribution to: Teplizumab. In WikiDoc. https://www.wikidoc.org/index.php?title=Teplizumab-mzwv
  42. Gibson CM, Singh PV. Contribution to: Hyperpolarized Xe-129. In WikiDoc. https://www.wikidoc.org/index.php?title=Hyperpolarized_Xe-129
  43. Gibson CM, Singh PV. Contribution to: Nirmatrelvir, ritonavir. In WikiDoc. https://www.wikidoc.org/index.php?title=Nirmatrelvir,_ritonavir
  44. Gibson CM, Singh PV. Contribution to: Flotufolastat F 18. In WikiDoc. https://www.wikidoc.org/index.php?title=Flotufolastat_F_18
  45. Gibson CM, Singh PV. Contribution to: Crovalimab. In WikiDoc. https://www.wikidoc.org/index.php?title=Crovalimab-akkz
  46. Gibson CM, Singh PV. Contribution to: Nemolizumab. In WikiDoc. https://www.wikidoc.org/index.php?title=Nemolizumab-ilto
  47. Gibson CM, Singh PV. Contribution to: Axatilimab. In WikiDoc. https://www.wikidoc.org/index.php?title=Axatilimab-csfr
  48. Gibson CM, Singh PV. Contribution to: Lebrikizumab. In WikiDoc. https://www.wikidoc.org/index.php?title=Lebrikizumab-lbkz
  49. Gibson CM, Singh PV. Contribution to: Xanomeline. In WikiDoc. https://www.wikidoc.org/index.php?title=Xanomeline_and_trospium_chloride
  50. Gibson CM, Singh PV. Contribution to: Flurpiridaz F 18. In WikiDoc. https://www.wikidoc.org/index.php?title=Flurpiridaz_F_18
  51. Gibson CM, Singh PV. Contribution to: Zanidatamab. In WikiDoc. https://www.wikidoc.org/index.php?title=Zanidatamab-hrii
  52. Gibson CM, Singh PV. Contribution to: Orlynvah. In WikiDoc. https://www.wikidoc.org/index.php?title=Orlynvah
  53. Gibson CM, Singh PV. Contribution to: Xanomeline and trospium chloride. In WikiDoc. https://www.wikidoc.org/index.php?title=Xanomeline_and_trospium_chloride
  54. Gibson CM, Singh PV. Contribution to: Berdazimer. In WikiDoc. https://www.wikidoc.org/index.php?title=Berdazimer
  55. Gibson CM, Singh PV. Contribution to: Elafibranor. In WikiDoc. https://www.wikidoc.org/index.php?title=Elafibranor
  56. Gibson CM, Singh PV. Contribution to: Sofpironium. In WikiDoc. https://www.wikidoc.org/index.php?title=Sofpironium
  57. Gibson CM, Singh PV. Contribution to: Ensifentrine. In WikiDoc. https://www.wikidoc.org/index.php?title=Ensifentrine
  58. Gibson CM, Singh PV. Contribution to: Vorasidenib. In WikiDoc. https://www.wikidoc.org/index.php?title=Vorasidenib
  59. Gibson CM, Singh PV. Contribution to: Givinostat. In WikiDoc. https://www.wikidoc.org/index.php?title=Givinostat
  60. Gibson CM, Singh PV. Contribution to: Duvyzat. In WikiDoc. https://www.wikidoc.org/index.php?title=Duvyzat
  61. Gibson CM, Singh PV. Contribution to: Palopegteriparatide. In WikiDoc. https://www.wikidoc.org/index.php?title=Palopegteriparatide
  62. Gibson CM, Singh PV. Contribution to: Seladelpar. In WikiDoc. https://www.wikidoc.org/index.php?title=Seladelpar
  63. Gibson CM, Singh PV. Contribution to: Lazertinib. In WikiDoc. https://www.wikidoc.org/index.php?title=Lazertinib
  64. Gibson CM, Singh PV. Contribution to: Mavorixafor. In WikiDoc. https://www.wikidoc.org/index.php?title=Mavorixafor
  65. Gibson CM, Singh PV. Contribution to: Imetelstat. In WikiDoc. https://www.wikidoc.org/index.php?title=Imetelstat
  66. Gibson CM, Singh PV. Contribution to: SOFDRA. In WikiDoc. https://www.wikidoc.org/index.php?title=SOFDRA
  67. Gibson CM, Singh PV. Contribution to: Acoramidis. In WikiDoc. https://www.wikidoc.org/index.php?title=Acoramidis

List of Chapters

  1. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php/Sepsis
  2. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis overview. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_overview
  3. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis pathophysiology. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_pathophysiology
  4. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis epidemiology and demographics. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_epidemiology_and_demographics
  5. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis natural history, complications and prognosis. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_natural_history,_complications_and_prognosis
  6. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis diagnostic criteria. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_diagnostic_criteria
  7. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis laboratory findings. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_laboratory_findings
  8. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis medical therapy. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_medical_therapy
  9. Gibson CM, Singh P, Singh PV. Contribution to: Sepsis future or investigational therapies. In WikiDoc. 11 August 2025. https://www.wikidoc.org/index.php?title=Sepsis_future_or_investigational_therapies
  10. Gibson CM, Singh PV. Contribution to: Drug coated balloon. In WikiDoc. 11 April 2025. https://www.wikidoc.org/index.php?title=Drug_coated_balloon
  11. Gibson CM, Singh PV. Contribution to:. Cardiac Optical Coherence Tomography. In WikiDoc. 7 May 2025. https://www.wikidoc.org/index.php?title=Cardiac_Optical_Coherence_Tomography_(OCT)
  12. Gibson CM, Singh PV. Contribution to:. Extracorporeal Membrane Oxygenation. In WikiDoc. 16 June 2025. https://www.wikidoc.org/index.php?title=Extracorporeal_Membrane_Oxygenation
  13. Gibson CM, Zorkun C, Guddeti R, Singh PV. Contribution to:. Obesity. In WikiDoc. 30 December 2025. https://www.wikidoc.org/index.php/Obesity
  14. Gibson CM, Singh PV. Contribution to:. Anti-obesity drug. In WikiDoc. 30 December 2025. http://www.wikidoc.org/index.php/Anti-obesity_drug
  15. Badgett RG, Singh PV. Contribution to:. Chronic pain medical therapy. In WikiDoc. 20 January 2026. https://www.wikidoc.org/index.php/Chronic_pain_medical_therapy
  16. Feinberg SD, Tariq MU, Singh PV. Contribution to:. Chronic pain. In WikiDoc. 20 January 2026. https://www.wikidoc.org/index.php/Chronic_pain
  17. Gibson CM, Marketkar S, Singh PV. Contribution to:. Neuralgia. In WikiDoc. 30 June 2025. https://www.wikidoc.org/index.php/Neuralgia
  18. Gibson CM, Singh PV. Contribution to:. Neuralgia medical therapy. In WikiDoc. 30 June 2025. https://www.wikidoc.org/index.php/Neuralgia_medical_therapy

Professional Experience

  • September 2024-Present
    • Research Scholar, Department of Cardiovascular Medicine, University Of Miami, Miami, Fl
  • October 2022-March 2024
    • House Officer, Heartline Cardiac Care Center, Prayagraj, India

Certifications

  • USMLE Step 1, Step 2ck, and Step 3 - 240, 258 and 244
  • TOEFL (Test of English as a Foreign Language) - 115/120
  • ECFMG (Educational Commission for Foreign Medical Graduates) Certified

Communication Languages

Retrieved from "https://www.wikidoc.org/index.php?title=User:Parth_Vikram_Singh&oldid=1742643"